Abstract: The present invention provides a process for preparing amorphous Cabazitaxel from the solvate form of Cabazitaxel. The present invention also provides novel diisopropyl ether solvate form of Cabazitaxel (I), and process for preparation thereof. Said amorphous Cabazitaxel and crystalline diisopropyl ether solvate of Cabazitaxel of the present invention can be utilized in preparing the pharmaceutical composition/s useful in the treatment of cancer.

Abstract: The present invention relates to a process for preparation of crystalline Form-SDI of Dasatinib (I). Said crystalline Form-SDI of Dasatinib is characterized by X-ray powder diffraction pattern comprising of at least seven 2?° peaks selected from the XRPD peak set of 5.8, 11.5, 12.7, 13.2, 17.3, 17.5, 18.1, 20.1, 20.5, 22.1, 25.4, 26.6, 26.8±0.20 2?°; IR spectrum having at least five absorption peaks selected from about 3390 cm?1, 2923 cm?1, 1621 cm?1, 1615 cm?1, 1537 cm?1, 1316 cm?1, 1061 cm?1, 815 cm?1 and 783 cm?1; and DSC isotherm comprising at least two endothermic peaks ranging between ?130° C. to 150° C., 160° C. to 175° C. or 280° C. to 290° C. The pharmaceutical compositions of the crystalline Form-SDI of Dasatinib or its hydrate thereof may be useful as an anti-cancer agent.

Abstract: The present invention provides a process for preparing amorphous Cabazitaxel from the solvate form of Cabazitaxel. The present invention also provides novel diisopropyl ether solvate form of Cabazitaxel (I), and process for preparation thereof. Said amorphous Cabazitaxel and crystalline diisopropyl ether solvate of Cabazitaxel of the present invention can be utilized in preparing the pharmaceutical composition/s useful in the treatment of cancer.

Abstract: The present invention relates to an improved process for preparation of Dasatinib monohydrate Formula A, comprising the steps of: a) reacting the compound of Formula I with 1-(2-Hydroxyethyl)piperazine (Formula II) in the presence of acetonitrile solvent, an organic base and a phase transfer catalyst; b) heating the reaction mixture at 50-80° C.; c) adding water to the reaction mass obtained in step b); d) cooling the reaction mixture to a temperature below 35° C.; e) filtering and drying the material obtained in step d); f) optionally purifying the product obtained from step e); g) isolating the crystalline Dasatinib monohydrate.

Abstract: The present invention provides an improved process for preparing N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazole carboxamide monohydrate or Dasatinib monohydrate (Formula A).